The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Immunotherapy has dramatically improved the treatment outcomes of primary lung cancer; however, it sometimes causes a serious ...

A doctor at the centre of a review of the treatment of more than 200 patients with lung disease is being investigated by the ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

More than 200 patients have had their lung disease treatment reviewed following concerns their care at a Surrey hospital did ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...